Clinical studies showed that combined CDK4/6i and letrozole significantly improve progression-free survival (PFS) compared to letrozole alone in advanced ER+ BC resulted in the approval of CDK4/6i in combination with an AI in first line treatment of this disease [69–71]. Here, CDK4 is linked to breast cancer.